Daiichi Sankyo shuts down a German R&D; shop
Daiichi Sankyo is closing up its German research outpost, shuttering the former U3 Pharma as it consolidates its global R&D; presence.
Beleaguered Daiichi Sankyo shuttering German antibody business
It's been rough lately for Daiichi Sankyo, and now, things are going from bad to worse. The beleaguered Japanese drugmaker is shuttering its German antibody subsidiary, months after it announced that it would cut half its U.S. workforce in a bid to revive business and prepare for the patent loss for its best-selling drug.
In the latest of a string a partnerships forged this year, Daiichi Sankyo is teaming up with Sanofi's Japanese unit to launch Squarekids subcutaneous injection syringe, a tetravalent vaccine for the prevention of diphtheria, pertussis, tetanus and polio.
Daiichi loses Supreme Court decision on Apotex generic
The U.S. Supreme Court dealt a blow to Daiichi Sankyo and Mylan Pharmaceuticals when the court declined to hear their appeal in their attempt to head off drugmaker Apotex from introducing a generic version of the hypertension drug Benicar.
Daiichi Sankyo and Plexxikon get FDA nod for melanoma combination
Japan's Daiichi Sankyo and its associated company Plexxikon said the U.S. Food and Drug Administration (FDA) has approved cobimetinib for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib), the company said in a statement.
Struggling Daiichi stumbles with vaccine production again
As if Daiichi Sankyo didn't have trouble enough, the struggling Japanese drugmaker, which is laying off thousands of employees to cut costs, is again having issues with its vaccine production.
Daiichi Sankyo's cancer drug wins the FDA's coveted 'breakthrough' tag
Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it moves toward approval.
Japan's Daiichi Sankyo to cut as many as 1,200 U.S. jobs in reorganization
Japan's Daiichi Sankyo will cut as many as 1,200 jobs in the U.S. as it braces for the loss of patent protection on top treatment Benicar and shakes up the organization for a transition to a specialty portfolio in cardiovascular, pain management and oncology.
Struggling Daiichi plots another 1,000-plus job cuts in U.S.
Japan-based drugmaker Daiichi Sankyo will cut up to 1,200 jobs in the U.S., about half its workforce in its stateside subsidiary, Nikkei reports. The announcement follows a series of layoffs earlier this year at its Parsippany, NJ, operations.
Japan's Daiichi Sankyo goes to Memphis to license clot-busting antibody
Japan's Daiichi Sankyo has licensed a candidate to treat ischemic stroke, TS23, from Memphis-based Translational Sciences without disclosing any details on fees, milestones and royalties for exclusive global development and commercial rights